Progression of X‐linked adrenoleukodystrophy under interferon‐β therapy
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
The cerebral phenotype of X‐linked adrenoleukodystrophy (ALD) is a rapidly progressive neurodegenerative disorder characterized by a cerebral inflammatory response and elevated very long‐chain fatty acids (VLCFA). Interferon‐β (INFB) is known to suppress the synthesis of tumour necrosis factor α and interferon‐γ, which have been reported to be elevated in the margin of the areas of demyelination in ALD brains. We report on treatment with interferon‐β in 8 patients with cerebral ALD, who additionally received glycerol trioleate/glycerol trierucate. INFB‐1a (Rebif, Serono, Switzerland) was given subcutaneously once a week, 3 million units for the first 3 months and 6 million units for the next 9 months. All patients showed an unimpeded progression of neurological symptoms during INFB therapy. Therapy was stopped within 6 months in 4 patients because of the fast neurological deterioration with loss of walking. In all patients the MRI demonstrated a progression of demyelination with a qualitatively unchanged gadolinium enhancement. Further studies are needed to elucidate the pathomechanism of demyelination in ALD in order to find an effective therapy for cerebral ALD patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adrenoleukodystrophy: A Clinical and Pathological Study of 17 Cases
Schaumburg, H. H. (1975) · Archives of Neurology · doi:10.1001/archneur.1975.00490510033001 · Cited by 475
POWERS, J. M., LIU, Y., MOSER, A. B., & MOSER, H. W. (1992) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199211000-00007 · Cited by 265
Adrenoleukodystrophy: Phenotypic variability and implications for therapy
Moser, H. W., Moser, A. B., Smith, K. D., Bergin, A., Borel, J., Shankroff, J., Stine, O. C., Merette, C., Ott, J., Krivit, W., et al. (1992) · Journal of Inherited Metabolic Disease · doi:10.1007/bf01799621 · Cited by 239
Naidu, S. (1988) · Archives of Neurology · doi:10.1001/archneur.1988.00520320032011 · Cited by 55
High dose immunoglobulin IV treatment in adrenoleukodystrophy.
Cappa, M., Bertini, E., del Balzo, P., Cambiaso, P., Di Biase, A., & Salvati, S. (1994) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.57.suppl.69 · Cited by 44
Adrenoleukodystrophy: Failure of Immunosuppression to Prevent Neurological Progression
Stumpf, D. A. (1981) · Archives of Neurology · doi:10.1001/archneur.1981.00510010074014 · Cited by 41
Cited by
Shapiro, E., Krivit, W., Lockman, L., Jambaqué, I., Peters, C., Cowan, M., Harris, R., Blanche, S., Bordigoni, P., Loes, D., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02629-5 · Cited by 329
Kemp, S., Pujol, A., Waterham, H. R., van Geel, B. M., Boehm, C. D., Raymond, G. V., Cutting, G. R., Wanders, R. J. A., & Moser, H. W. (2001) · Human Mutation · doi:10.1002/humu.1227 · Cited by 321
van Geel, B. M., Assies, J., Haverkort, E. B., Koelman, J. H. T. M., Verbeeten, B., Wanders, R. J. A., & Barth, P. G. (1999) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.67.3.290 · Cited by 131
Lee, C. A. A., Seo, H. S., Armien, A. G., Bates, F. S., Tolar, J., & Azarin, S. M. (2018) · Fluids and Barriers of the CNS · doi:10.1186/s12987-018-0094-5 · Cited by 52
Haematopoietic stem cell transplantation in 12 patients with cerebral X-linked adrenoleukodystrophy
Baumann, M., Korenke, C., Weddige-Diedrichs, A., Wilichowski, E., Hunneman, D., Wilken, B., Brockmann, K., Klingebiel, T., Niethammer, D., Kühl, J., et al. (2003) · European Journal of Pediatrics · doi:10.1007/s00431-002-1097-3 · Cited by 47
Self-citation
Metadata
- Authors
- Korenke, G. C., Christen, H. ‐., Kruse, B., Hunneman, D. H., & Hanefeld, F.
- Venue
- Journal of Inherited Metabolic Disease
- Publisher
- Wiley
- Published
- 1997-03
- Volume
- 20
- Issue
- 1
- Pages
- 59-66
- ISSN
- 0141-8955 (ISSN-L)
- 1573-2665
- OpenAlex
- W137925544
- Cited by
- 29
- References
- 6
- FWCI
- 0.85
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Progression of X‐linked adrenoleukodystrophy under interferon‐β therapy. https://app.cochat.ai/papers/10.1023/a:1005361607523
- The paper
- Korenke, G. C., Christen, H. ‐., Kruse, B., Hunneman, D. H., & Hanefeld, F. (1997). Progression of X‐linked adrenoleukodystrophy under interferon‐β therapy. Journal of Inherited Metabolic Disease. https://doi.org/10.1023/a%3A1005361607523
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.